Irsicaixa

Irsicaixa company information, Employees & Contact Information

Explore related pages

Related company profiles:

IrsiCaixa is a leading research institute in infections and immunity, jointly driven by the "la Caixa" Foundation and the Department of Health of the Government of Catalonia. Established in 1995 as a private non-profit foundation, with the primary goal of finding a solution to the then-devastating HIV/AIDS pandemic, IrsiCaixa brings together extensive knowledge in the field of infectious diseases and the immune system. While maintaining a strong commitment to eradicating HIV, more than 100 dedicated researchers explore other viral, bacterial, and fungal infections with significant clinical impact, such as COVID-19, syphilis, and Ebola, as well as diseases caused by respiratory syncytial virus and multidrug-resistant bacteria. IrsiCaixa leverages its extensive knowledge in immunology and vaccines to combat a broad spectrum of diseases and to reduce the impact of infections. Additionally, its scientific trajectory has led it to engage in other cross-cutting disciplines, such as understanding the role of microorganisms and the resulting immunological disorders to address medical challenges like cancer, Alzheimer's, aging, and the microbiome.

Company Details

Employees
115
Founded
-
Address
Irsicaixa. Hospital Germans Trias I Pujol. Ctra Del Canyet, S/n, Badalona,barcelona 08916,spain
Phone
(34) 93 465 63 74
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
Badalona, Barcelona
Looking for a particular Irsicaixa employee's phone or email?

Irsicaixa Questions

News

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors - ScienceDirect.com

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors ScienceDirect.com

Massive endocytosis mechanisms are involved in uptake of HIV-1 particles by monocyte-derived dendritic cells - Frontiers

Massive endocytosis mechanisms are involved in uptake of HIV-1 particles by monocyte-derived dendritic cells Frontiers

Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study - The Lancet

Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study The Lancet

Journal of Internal Medicine - Wiley Online Library

Journal of Internal Medicine Wiley Online Library

Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection - medRxiv

Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection medRxiv

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment - Frontiers

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment Frontiers

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes - ScienceDirect.com

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes ScienceDirect.com

Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities - medRxiv

Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities medRxiv

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study - The Lancet

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study The Lancet

Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern - Frontiers

Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern Frontiers

Post COVID-19 Condition in Children and Adolescents: An Emerging Problem - Frontiers

Post COVID-19 Condition in Children and Adolescents: An Emerging Problem Frontiers

Interactions between gut microbiota, plasma metabolome and brain function in the setting of a HIV cure trial - Frontiers

Interactions between gut microbiota, plasma metabolome and brain function in the setting of a HIV cure trial Frontiers

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals - Frontiers

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals Frontiers

IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation - Frontiers

IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation Frontiers

Impact of COVID-19 lockdown in a biomedical research campus: A gender perspective analysis - Frontiers

Impact of COVID-19 lockdown in a biomedical research campus: A gender perspective analysis Frontiers

Lamivudine modulates the expression of neurological impairment-related genes and LINE-1 retrotransposons in brain tissues of a Down syndrome mouse model - Frontiers

Lamivudine modulates the expression of neurological impairment-related genes and LINE-1 retrotransposons in brain tissues of a Down syndrome mouse model Frontiers

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen - Frontiers

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen Frontiers

Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections - Frontiers

Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections Frontiers

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies - Frontiers

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies Frontiers

Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery - Frontiers

Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery Frontiers

Extremely low viral reservoir in treated chronically HIV-1-infected individuals - The Lancet

Extremely low viral reservoir in treated chronically HIV-1-infected individuals The Lancet

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis - Frontiers

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis Frontiers

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome - The Lancet

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome The Lancet

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination - The Lancet

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination The Lancet

Gut Microbiota Linked to Sexual Preference and HIV Infection - The Lancet

Gut Microbiota Linked to Sexual Preference and HIV Infection The Lancet

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study) - The Lancet

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study) The Lancet

(PDF) VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies - researchgate.net

(PDF) VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies researchgate.net

HIV entry inhibitors - The Lancet

HIV entry inhibitors The Lancet

Top Irsicaixa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant